Literature DB >> 24780213

Staging for hepatocellular carcinoma: complex and confusing.

Morris Sherman1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24780213     DOI： 10.1053/j.gastro.2014.04.026

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  12 in total

Review 1.  Transcatheter embolization therapy in liver cancer: an update of clinical evidences.

Authors:  Yì-Xiáng J Wáng; Thierry De Baere; Jean-Marc Idée; Sébastien Ballet
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

Review 2.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

3.  Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.

Authors:  Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul
Journal:  Nat Rev Clin Oncol       Date:  2014-11-25       Impact factor: 66.675

Review 4.  Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology.

Authors:  Jan Hansmann; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

Review 5.  Surgical treatment of hepatocellular carcinoma: should resection be performed according to Barcelona Clinic Liver Cancer classification?

Authors:  Josep Fuster
Journal:  Hepat Oncol       Date:  2015-07-30

6.  Immunohistochemical Coexpression of Epithelial Cell Adhesion Molecule and Alpha-Fetoprotein in Hepatocellular Carcinoma.

Authors:  Leonardo do Prado Lima; Carla Jorge Machado; João Bernardo Sancio Rocha Rodrigues; Leonardo de Souza Vasconcellos; Eduardo Paulino Junior; Paula Vieira Teixeira Vidigal; Vivian Resende
Journal:  Can J Gastroenterol Hepatol       Date:  2018-07-19

7.  Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology.

Authors:  Po-Hong Liu; Chia-Yang Hsu; Yun-Hsuan Lee; Chien-Wei Su; Cheng-Yuan Hsia; Yi-Hsiang Huang; Yi-You Chiou; Han-Chieh Lin; Teh-Ia Huo
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

8.  SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma.

Authors:  Yun Hak Kim; Dae Cheon Jeong; Kyoungjune Pak; Myoung-Eun Han; Ji-Young Kim; Liu Liangwen; Hyun Jin Kim; Tae Woo Kim; Tae Hwa Kim; Dong Woo Hyun; Sae-Ock Oh
Journal:  Oncotarget       Date:  2017-08-14

9.  Development and Validation of a Prognostic Nomogram in AFP-negative hepatocellular carcinoma.

Authors:  Xueping Wang; Minjie Mao; Zhonglian He; Lin Zhang; Huilan Li; Jianhua Lin; Yi He; Shuqin Dai; Wanming Hu; Wanli Liu
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

10.  Nomograms to predict the long-time prognosis in patients with alpha-fetoprotein negative hepatocellular carcinoma following radical resection.

Authors:  Jian Huang; Fu-Chen Liu; Li Li; Wei-Ping Zhou; Bei-Ge Jiang; Ze-Ya Pan
Journal:  Cancer Med       Date:  2020-02-25       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.